These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 6802550)

  • 1. 1-Alpha-hydroxy vitamin D in dialysis bone disease: radiological changes after 6 and 12 months of treatment.
    Robinson PJ; Walker GS; Peacock M; McLachlan MS; Davison AM
    Clin Radiol; 1982 Jan; 33(1):9-17. PubMed ID: 6802550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of osteitis fibrosa, aluminium bone disease and soft-tissue calcification in dialysis patients: a long-term comparison of moderate doses of oral calcium +/- Mg(OH)2 vs Al(OH)3 +/- 1 alpha OH vitamin D3.
    Morinière P; Boudailliez B; Hocine C; Belbrik S; Renaud H; Westeel PF; Solal MC; Fournier A
    Nephrol Dial Transplant; 1989; 4(12):1045-53. PubMed ID: 2517325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An evaluation of 1 alpha-hydroxy-and 1,25-dihydroxyvitamin D3 in the treatment of renal bone disease.
    Kanis JA; Russell RG; Cundy T; Earnshaw M; Woods CG; Smith R; Heynen G
    Contrib Nephrol; 1980; 18():12-28. PubMed ID: 7353370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Periosteal new bone formation developing during haemodialysis for chronic renal failure.
    Ritchie WG; Winney RJ; Davison AM; Robson JS
    Br J Radiol; 1975 Aug; 48(572):656-61. PubMed ID: 810201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dialysis osteodystrophy. A study involving 94 patients.
    Chan YL; Furlong TJ; Cornish CJ; Posen S
    Medicine (Baltimore); 1985 Sep; 64(5):296-309. PubMed ID: 3839891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal ostodystrophy during the developing stage of maintenance dialysis in Transylvania. Early development of periarticular calcifications and beta 2 microglobulin amyloidosis in spite of a relatively good prevention of secondary hyperparathyroidism.
    Oprisiu R; Bolosiu H; Boca I; Theodoru C; Elefterescu R; Brazier M; el Esper I; Leflon P; Ledeme C; Fournier A; Heinze V
    Ann Med Interne (Paris); 1998 Mar; 149(2):67-75. PubMed ID: 11490527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1-alpha-Hydroxyvitamin D3 derivatives in the treatment of renal bone diseases: justification and optimal modalities of administration.
    Fournier A; Morinière PH; Oprisiu R; Yverneau-Hardy P; Westeel PF; Mazouz H; el Esper N; Ghazali A; Boudailliez B
    Nephron; 1995; 71(3):254-83. PubMed ID: 8569975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of hyperparathyroidism in patients on maintenance dialysis by intravenous 1-alpha-hydroxyvitamin D3 in association with Mg(OH)2 as sole phosphate binder. A randomized comparative study with the association CaCO3 +/- Mg(OH)2.
    Mornière P; Maurouard C; Boudailliez B; Westeel PF; Achard JM; Boitte F; el Esper N; Compagnon M; Maurel G; Bouillon R
    Nephron; 1992; 60(2):154-63. PubMed ID: 1552999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic 1alpha-hydroxyvitamin D3 therapy in haemodialysis patients.
    Walker GS; Peacock M; Aaron J; Robinson PJ; Davison AM
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():125s-130s. PubMed ID: 606410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal osteopenia - an assessment of long-term therapy with vitamin D analogues.
    Catto GR; Junor BJ; Fraser RA; Smith FW; Ettinger KV; Edward N; MacLeod M
    Proc Eur Dial Transplant Assoc; 1979; 16():637-43. PubMed ID: 232916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term experience of alfacalcidol in renal osteodystrophy.
    Sharman VL; Brownjohn AM; Goodwin FJ; Hately W; Manning RM; O'Riordan JH; Papapoulos SE; Marsh FP
    Q J Med; 1982; 51(203):271-8. PubMed ID: 7146311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of renal bone disease with 1 alpha-hydroxylated derivatives of vitamin D3. Clinical, biochemical, radiographic and histological responses.
    Kanis JA; Cundy T; Earnshaw M; Henderson RG; Heynen G; Naik R; Russell RG; Smith R; Woods CG
    Q J Med; 1979 Apr; 48(190):289-322. PubMed ID: 504552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal osteodystrophy. Effect of hemodialysis and 1 alpha-hydroxy vitamin D3 on bone lesions and metacarpal bone mass.
    Andresen J; Nielsen HE; Johannsen A
    Acta Radiol Diagn (Stockh); 1980; 21(4):541-4. PubMed ID: 7457184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of clinical, biochemical and skeletal responses to 1alpha-hydroxyvitamin D3 in renal bone disease.
    Kanis JA; Earnshaw M; Henderson RG; Heynen G; Ledingham JG; Naik RB; Oliver DO; Russell RG; Smith R; Wilkinson RH; Woods CG
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():45s-50s. PubMed ID: 606424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical, histological, and chemical characterization of ectopic calcification in dialyzed and non-dialyzed patients.
    Portigliatti Barbos M; Cadario A; Canavese C; Pavan I
    Ital J Orthop Traumatol; 1991 Dec; 17(4):523-32. PubMed ID: 1816158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Radiological study of the hand of patients undergoing periodic hemodialysis. Possibilities and limitations of the method as an index of the evolution of the uremic disease].
    Fabbri L; Fusaroli M; Losinno F; Pavlica P; Stasi G; Viglietta G
    Radiol Med; 1979; 65(1-2):11-9. PubMed ID: 461842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis.
    Brandi L; Daugaard H; Nielsen PK; Jensen LT; Egsmose C; Olgaard K
    Nephron; 1996; 74(1):89-103. PubMed ID: 8883025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of 1 alpha-OH-vitamin D3 and high doses of calcium carbonate for the control of hyperparathyroidism and hyperaluminemia in patients on maintenance dialysis.
    Morinière P; Fournier A; Leflon A; Hervé M; Sebert JL; Grégoire I; Bataille P; Guéris J
    Nephron; 1985; 39(4):309-15. PubMed ID: 3982576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1 alpha-hydroxy vitamin D3 treatment of non-dialyzed patients with chronic renal failure. Effects on bone, mineral metabolism and kidney function.
    Nielsen HE; Rømer FK; Melsen F; Christensen MS; Hansen HE
    Clin Nephrol; 1980 Mar; 13(3):103-8. PubMed ID: 7379358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.